BR0109729A - Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese - Google Patents

Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese

Info

Publication number
BR0109729A
BR0109729A BR0109729-6A BR0109729A BR0109729A BR 0109729 A BR0109729 A BR 0109729A BR 0109729 A BR0109729 A BR 0109729A BR 0109729 A BR0109729 A BR 0109729A
Authority
BR
Brazil
Prior art keywords
agent
angiogenic
angiogenesis
combination
effect
Prior art date
Application number
BR0109729-6A
Other languages
English (en)
Inventor
Jon Owen Curwen
Donald James Ogilvie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0109729A publication Critical patent/BR0109729A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"USO DE UMA COMBINAçãO DE UM AGENTE ANTI-ANGIOGêNICO E UM AGENTE ANTI-HIPERTENSIVO, KIT PARA USO NA PRODUçãO DE UM EFEITO ANTI-ANGIOGêNICO E/OU EFEITO REDUTOR DA PERMEABILIDADE VASCULAR EM UM ANIMAL DE SANGUE QUENTE, E, MéTODO DE TRATAMENTO DE UM ESTADO DOENTIO ASSOCIADO COM A ANGIOGêNESE". A invenção refere-se ao uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, para uso na fabricação de um medicamento para o tratamento de um estado doentio associado com uma angiogênese em um mamífero de sangue quente, tal como um ser humano. A invenção também refere-se a composições farmacêuticas compreendendo um agente anti-angiogênico e um agente hipertensivo, uma seus kits e uma um método de tratamento de um estado doentio associado com uma angiogênese, que compreende uma administração de uma quantidade eficaz de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo uma um animal de sangue quente, tal como um ser humano.
BR0109729-6A 2000-04-05 2001-04-02 Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese BR0109729A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008269.3A GB0008269D0 (en) 2000-04-05 2000-04-05 Combination chemotherapy
PCT/GB2001/001522 WO2001074360A1 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents

Publications (1)

Publication Number Publication Date
BR0109729A true BR0109729A (pt) 2003-02-04

Family

ID=9889176

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109729-6A BR0109729A (pt) 2000-04-05 2001-04-02 Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese

Country Status (29)

Country Link
US (1) US7829573B2 (pt)
EP (3) EP1658849A3 (pt)
JP (1) JP2003528917A (pt)
KR (2) KR20080034523A (pt)
CN (1) CN1431902A (pt)
AT (1) ATE355065T1 (pt)
AU (2) AU2001244386B2 (pt)
BR (1) BR0109729A (pt)
CA (1) CA2401854A1 (pt)
CY (1) CY1107615T1 (pt)
CZ (1) CZ299410B6 (pt)
DE (1) DE60126923T2 (pt)
DK (1) DK1272186T3 (pt)
EE (1) EE200200578A (pt)
ES (1) ES2280349T3 (pt)
GB (1) GB0008269D0 (pt)
HU (1) HUP0300426A2 (pt)
IL (1) IL151503A0 (pt)
IS (2) IS2455B (pt)
MX (1) MXPA02009743A (pt)
NO (2) NO323467B1 (pt)
NZ (2) NZ534455A (pt)
PL (1) PL357605A1 (pt)
PT (1) PT1272186E (pt)
RU (1) RU2002129353A (pt)
SI (1) SI1272186T1 (pt)
SK (1) SK14302002A3 (pt)
WO (1) WO2001074360A1 (pt)
ZA (1) ZA200206959B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
IL149034A0 (en) 1999-11-05 2002-11-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
ATE300303T1 (de) 2000-03-06 2005-08-15 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
KR100858069B1 (ko) * 2000-04-07 2008-09-22 아스트라제네카 아베 퀴나졸린 화합물류
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US7268230B2 (en) * 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
KR20040103964A (ko) * 2002-04-16 2004-12-09 아스트라제네카 아베 암 치료를 위한 조합 요법
US7358236B1 (en) 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
EP2280003B1 (en) * 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
EP1575416B1 (en) * 2002-07-19 2013-10-02 Beth Israel Deaconess Medical Center Methods of diagnosing pre-eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
EP1562955B1 (en) 2002-11-04 2008-02-27 Astrazeneca AB Quinazoline derivatives as src tyrosine kinase inhibitors
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
MXPA05013827A (es) * 2003-06-18 2006-03-13 Angiogene Pharm Ltd Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
KR20060033782A (ko) * 2003-07-10 2006-04-19 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관투과성 관련 질환 치료 용도
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0318422D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
DE602004017479D1 (de) 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
AU2004309166B2 (en) * 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
MXPA06010755A (es) * 2004-03-23 2006-12-15 Astrazeneca Ab Terapia de combinacion.
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
US20070142308A1 (en) * 2005-04-06 2007-06-21 Helmut Augustin Angiogenesis-affecting compounds and methods for use thereof
US20070142433A1 (en) * 2004-04-06 2007-06-21 Helmut Augustin Angiogenesis-affecting compounds and methods of use thereof
WO2005097121A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
WO2005110462A2 (en) * 2004-05-04 2005-11-24 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
MX2007003522A (es) * 2004-09-24 2007-06-11 Beth Israel Hospital Complicaciones del embarazo.
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
MX2007003505A (es) * 2004-09-27 2007-05-10 Astrazeneca Ab Combinacion que comprende zd6474 e imatinib.
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
US7534806B2 (en) 2004-12-06 2009-05-19 Avigen, Inc. Method for treating neuropathic pain and associated syndromes
BRPI0519096A2 (pt) * 2004-12-15 2008-12-23 Beth Israel Hospital Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez
JP2008537538A (ja) 2005-02-11 2008-09-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ拮抗剤及び降圧剤の治療的組み合わせ
EP1858520B1 (en) * 2005-03-09 2011-10-05 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
CA2614002A1 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
EP1915368A1 (en) 2005-08-08 2008-04-30 Pfizer, Inc. Salts and polymorphs of a vergf-r inhibitor
EP1917024A2 (en) * 2005-08-12 2008-05-07 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a vegf antagonist
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
ES2399768T3 (es) * 2006-09-29 2013-04-03 Astrazeneca Ab Combinación de ZD6474 y bevacizumab para terapia del cáncer
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
WO2008094571A1 (en) * 2007-01-30 2008-08-07 Avigen, Inc. Methods for treating acute and subchronic pain
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
AU2008248188A1 (en) * 2007-05-02 2008-11-13 Tau Therapeutics Llc Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
JP2010533177A (ja) * 2007-07-10 2010-10-21 メルク・シャープ・エンド・ドーム・コーポレイション キナゾリノンｔ型カルシウムチャネル拮抗薬
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
WO2011109262A2 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN103110614B (zh) * 2013-01-18 2015-02-18 杭州雷索药业有限公司 舒洛地尔在制备抗血管生成类药物中的应用
EP3763710A1 (en) * 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
SG11201607795UA (en) 2014-04-08 2016-10-28 Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US10265111B2 (en) 2016-04-26 2019-04-23 Medtronic Holding Company Sárl Inflatable bone tamp with flow control and methods of use
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
WO2020028007A1 (en) * 2018-07-31 2020-02-06 Colorado State University Research Foundation Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11484355B2 (en) 2020-03-02 2022-11-01 Medtronic Holding Company Sàrl Inflatable bone tamp and method for use of inflatable bone tamp

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5646136A (en) 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) * 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
WO1997032856A1 (en) * 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
WO1997034876A1 (en) * 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6809097B1 (en) * 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998028006A1 (en) 1996-12-23 1998-07-02 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
ES2289791T3 (es) * 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
DK1064382T3 (da) * 1998-03-17 2008-12-08 Genentech Inc Homologe polypeptider til VEGF og BMP1
US6191144B1 (en) * 1998-08-17 2001-02-20 Warner-Lambert Company Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis
ES2211165T3 (es) 1998-09-09 2004-07-01 Scios Inc. Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.
CA2359461A1 (en) * 1999-01-15 2000-07-20 Medstar Research Institute Inhibiting development of microvessels within vascular walls
CZ303692B6 (cs) * 1999-02-10 2013-03-13 Astrazeneca Ab Chinazolinové deriváty jako inhibitory angiogeneze
IL149034A0 (en) * 1999-11-05 2002-11-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
EP1303501B1 (en) * 2000-07-13 2005-09-21 Alteon, Inc. Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP2006502132A (ja) 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 癌の治療における血管内皮細胞増殖因子受容体の阻害薬ｚｄ６４７４と放射線療法との併用
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
KR20060033782A (ko) 2003-07-10 2006-04-19 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관투과성 관련 질환 치료 용도
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0406445D0 (en) 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
MXPA06010755A (es) * 2004-03-23 2006-12-15 Astrazeneca Ab Terapia de combinacion.
MX2007003505A (es) * 2004-09-27 2007-05-10 Astrazeneca Ab Combinacion que comprende zd6474 e imatinib.
MX2007003506A (es) * 2004-09-27 2007-05-10 Aztrazeneca Ab Terapia de combinacion de cancer que comprende azd2171 e imatinib.
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2614002A1 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
CA2633211A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물
ES2399768T3 (es) 2006-09-29 2013-04-03 Astrazeneca Ab Combinación de ZD6474 y bevacizumab para terapia del cáncer
WO2008125820A1 (en) 2007-04-13 2008-10-23 Astrazeneca Ab Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii

Also Published As

Publication number Publication date
SI1272186T1 (sl) 2007-06-30
SK14302002A3 (sk) 2003-05-02
CY1107615T1 (el) 2013-03-13
GB0008269D0 (en) 2000-05-24
ZA200206959B (en) 2003-12-01
NZ534455A (en) 2007-01-26
WO2001074360A1 (en) 2001-10-11
DK1272186T3 (da) 2007-05-21
ATE355065T1 (de) 2006-03-15
IS8726A (is) 2008-04-16
EP1790340A2 (en) 2007-05-30
EP1658849A3 (en) 2009-02-18
EP1272186A1 (en) 2003-01-08
IL151503A0 (en) 2003-04-10
NO326277B1 (no) 2008-10-27
JP2003528917A (ja) 2003-09-30
AU4438601A (en) 2001-10-15
US20030144298A1 (en) 2003-07-31
NO20024814D0 (no) 2002-10-04
KR100849149B1 (ko) 2008-07-31
ES2280349T3 (es) 2007-09-16
NO20024814L (no) 2002-11-12
IS2455B (is) 2008-11-15
EP1658849A2 (en) 2006-05-24
HUP0300426A2 (hu) 2003-06-28
KR20030007491A (ko) 2003-01-23
PT1272186E (pt) 2007-04-30
PL357605A1 (en) 2004-07-26
NO323467B1 (no) 2007-05-21
US7829573B2 (en) 2010-11-09
EP1272186B1 (en) 2007-02-28
CZ299410B6 (cs) 2008-07-16
NZ520938A (en) 2005-08-26
DE60126923D1 (de) 2007-04-12
DE60126923T2 (de) 2007-10-31
RU2002129353A (ru) 2004-03-20
AU2001244386B2 (en) 2005-01-27
KR20080034523A (ko) 2008-04-21
EE200200578A (et) 2004-06-15
MXPA02009743A (es) 2003-03-27
EP1790340A3 (en) 2009-03-18
IS6557A (is) 2002-09-20
CN1431902A (zh) 2003-07-23
CA2401854A1 (en) 2001-10-11
NO20062050L (no) 2001-10-08

Similar Documents

Publication Publication Date Title
BR0109729A (pt) Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
PE20001032A1 (es) Composiciones y metodos para tratar enfermedades pulmonares
BR9915800A (pt) Produto terapêutico para supressão dos ruìdos de ronco
MEP26808A (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
BR0111335A (pt) Derivado de quinazolina, processo para a preparação de um derivado de, quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
BR0013897A (pt) Uso de ácido linoleico conjugado (cla) ou de um seu derivado, composição tópica cosmética ou dermatológica, e, método de tratamento e/ou de profilaxia de celulite e de depósitos de gordura
BR9914954A (pt) Implante com cavidades contendo agentes terapêuticos
DE69930259D1 (de) Zusammensetzungen zur anwendung von entzündungshemmenden, insbesondere antiseptischen und/oder wundheilenden wirkstoffen im oberen atemwegtrakt und/oder ohr
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
WO2003034995A3 (en) Integrin targeting compounds
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BRPI0409742A (pt) uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica
DE60127970D1 (de) Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
SE0004101D0 (sv) New use
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR9917389B1 (pt) formulaÇÕes tàpicas compreendendo agentes de penetraÇço na pele e o uso das mesmas.
BR0009194A (pt) Composição do resorcinol
BRPI0409387B8 (pt) complexo de alvejamento de tecido mole de tório-227 e um agente complexante, uso do mesmo, composição farmacêutica, método para a formação de um complexo, e, kit para uso em um método para o tratamento de doença de tecido mole em um indivíduo mamífero
BR0314445A (pt) Produto interlabial e folha lateral do mesmo capaz de se desintegrar na água; corpo envoltório; fibra de fibrila e método para melhorar a estabilidade de uma fibra hidrofìlica

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA A INT. CL A61K 31/517, 31/505, 31/40, A61P 5/50, 9/00, 9/12, 17/06, 29/00, 27/00, 35/00, 37/00, 43/00

Ipc: A61K 31/517 (2010.01), A61K 31/505 (2010.01), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S)8O, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.